Gwen A. Melincoff - Sep 3, 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: Director
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Stock symbol: PLX
Transactions as of: Sep 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/4/2025, 05:00 PM
Previous filing: Jun 25, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Melincoff Gwen A	Director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL	/s/ Joseph R. Magnas, Attorney-in-Fact	2025-09-04	0001614890

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Award		+7.5K			7.5K	Sep 3, 2025	By Trust	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLX	Stock Options (Right to Buy)	Award	$0	+15K		$0.00	15K	Sep 3, 2025	Common Stock	15K	$1.64	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
F2	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.
F3	The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
F4	Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.